Response to comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125.
作者信息
Gale Edwin A M
机构信息
Corresponding author: Edwin A.M. Gale,
出版信息
Diabetes Care. 2013 Dec;36(12):e214. doi: 10.2337/dc13-1542.
Abstract
摘要
相似文献
1
Response to comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125.对关于Butler等人的评论的回应：基于肠促胰岛素疗法临床应用的批判性分析：GLP-1疗法安全吗？《糖尿病护理》2013年；36:2118 - 2125。
Diabetes Care. 2013 Dec;36(12):e214. doi: 10.2337/dc13-1542.
2
Comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125.评论：巴特勒等人。对基于肠促胰岛素疗法临床应用的批判性分析：GLP-1疗法安全吗？《糖尿病护理》2013年；36:2118 - 2125。
Diabetes Care. 2013 Dec;36(12):e213. doi: 10.2337/dc13-1134.
3
Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.评论：巴特勒等人。在患有外分泌胰腺发育异常增加且有产生胰高血糖素的神经内分泌肿瘤潜在风险的人类中，肠促胰岛素疗法使外分泌和内分泌胰腺显著扩张。《糖尿病》2013年；62卷：2595 - 2604页。
Diabetes. 2013 Oct;62(10):e18. doi: 10.2337/db13-0525.
4
Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.评论：巴特勒等人。在患有外分泌胰腺发育异常增加及存在产生胰高血糖素的神经内分泌肿瘤可能性的人类中，肠促胰岛素疗法可使外分泌和内分泌胰腺显著扩张。《糖尿病》2013年；62卷：2595 - 2604页。
Diabetes. 2013 Oct;62(10):e16-7. doi: 10.2337/db13-0690.
5
A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?基于肠促胰岛素的治疗方法的临床应用的批判性分析：GLP-1 治疗方法安全吗？
Diabetes Care. 2013 Jul;36(7):2118-25. doi: 10.2337/dc12-2713. Epub 2013 May 3.
6
Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.明确肠促胰岛素疗法在 2 型糖尿病治疗中的作用。
Clin Ther. 2011 May;33(5):511-27. doi: 10.1016/j.clinthera.2011.04.015.
7
Response to comments on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.对关于以下内容的评论的回应：巴特勒等人。在患有外分泌胰腺发育异常增加和产生胰高血糖素的神经内分泌肿瘤潜在风险的人类中，肠促胰岛素治疗使外分泌和内分泌胰腺显著扩张。《糖尿病》2013年；62卷：2595 - 2604页。
Diabetes. 2013 Oct;62(10):e19-22. doi: 10.2337/db13-0996.
8
Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.区分肠促胰岛素治疗：2 型糖尿病的多靶点方法。
J Clin Pharm Ther. 2012 Oct;37(5):510-24. doi: 10.1111/j.1365-2710.2012.01342.x. Epub 2012 Mar 21.
9
Incretin-based therapies: can we achieve glycemic control and cardioprotection?基于肠促胰岛素的治疗：我们能否实现血糖控制和心脏保护？
J Endocrinol. 2014 Mar 7;221(1):T17-30. doi: 10.1530/JOE-13-0195. Print 2014 Apr.
10
Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.基于肠降血糖素的 2 型糖尿病治疗药物：特性、功能和临床意义。
Am J Med. 2011 Jan;124(1 Suppl):S3-18. doi: 10.1016/j.amjmed.2010.11.002.
本文引用的文献
1
Comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125.评论：巴特勒等人。对基于肠促胰岛素疗法临床应用的批判性分析：GLP-1疗法安全吗？《糖尿病护理》2013年；36:2118 - 2125。
Diabetes Care. 2013 Dec;36(12):e213. doi: 10.2337/dc13-1134.
2
Pressure mounts for companies to hand over data on antidiabetes drugs linked to pancreatic harm.各公司面临越来越大的压力，要求它们交出与胰腺损伤有关的抗糖尿病药物的数据。
BMJ. 2013 Jun 17;346:f3900. doi: 10.1136/bmj.f3900.
3
Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?胰高血糖素抑制糖尿病药物导致的胰腺损伤是否被低估了？
BMJ. 2013 Jun 7;346:f3680. doi: 10.1136/bmj.f3680.
4
A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?基于肠促胰岛素的治疗方法的临床应用的批判性分析：GLP-1 治疗方法安全吗？
Diabetes Care. 2013 Jul;36(7):2118-25. doi: 10.2337/dc12-2713. Epub 2013 May 3.
5
Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.外分泌和内分泌胰腺在具有外分泌胰腺发育不良增加的人类中随着肠促胰岛素治疗而显著扩张，并且具有产生胰高血糖素的神经内分泌肿瘤的潜力。
Diabetes. 2013 Jul;62(7):2595-604. doi: 10.2337/db12-1686. Epub 2013 Mar 22.
6
The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis.利拉鲁肽治疗对雄性和雌性 ZDF 大鼠内分泌和外分泌胰腺的影响：一项定量和定性分析，未发现药物引起胰腺炎的证据。
Am J Physiol Endocrinol Metab. 2012 Jul 15;303(2):E253-64. doi: 10.1152/ajpendo.00182.2012. Epub 2012 May 15.
7
The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.人 GLP-1 类似物利拉鲁肽与胰腺：三种动物模型中胰腺结构无改变的证据。
Diabetes. 2012 May;61(5):1243-9. doi: 10.2337/db11-0936. Epub 2012 Feb 14.
8
Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.外源性 GLP-1 受体激动剂 exendin-4 持续激活可诱导大鼠胰管腺扩张，并加速 Kras(G12D) 小鼠模型中发育不良病变和慢性胰腺炎的形成。
Diabetes. 2012 May;61(5):1250-62. doi: 10.2337/db11-1109. Epub 2012 Jan 20.
Zotero 插件